E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
JNJ-39756979 is being developed for the treatment of asthma. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To evaluate the safety and efficacy (in terms of improvement in pre-bronchodilator FEV1) of once daily oral administration of JNJ-39758979 in the treatment of adults with persistent asthma as defined by Global Initiative for Asthma (GINA) guidelines. |
|
E.2.2 | Secondary objectives of the trial |
•To evaluate the efficacy of JNJ-39758979 in terms of changes in:
-FVC -FEF25-75 -FEV1/FVC -Asthma Daily Diary data [AM and PM peak expiratory flow rates (PEFR), extent of albuterol/salbutamol use, presence of nocturnal awakenings, asthma symptom score] -Worsening of asthma
•To explore the relationship between pharmacokinetics and pharmacodynamic measurements.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Sputum Induction Substudy (at selected sites if technically feasible):
•Sputum induction: Sputum will be analyzed for cell counts, RNA and other biomarkers in the sputum supernatants and cell pellets which may include but are not limited to IL-8, IL-4, IL-5, IL-13, Muc5ac and IFN •PBMC FACS and ex-vivo challenge: PBMC will be purified and ex vivo challenge experiments will be carried out to inflammatory markers by immunochemistry and FACS analysis. Enrollment into the sputum induction substudy will continue until samples through Week 12 from approximately 24 subjects have been collected.
|
|
E.3 | Principal inclusion criteria |
1. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. 2. To participate in the optional pharmacogenomic component of this study, subjects (or their legally acceptable representative) must have signed the informed consent form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study (where local regulations permit). Refusal to consent for this component does not exclude a subject from participation in the clinical study. 3. Man or woman between 18 and 65 years of age, inclusive 4. Healthy on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening. 5. Chest x-ray performed within the past 6 months without clinically significant abnormalities. 6. Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, coagulation tests, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal as not clinically significant or as appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator. 7. Medically confirmed diagnosis of persistent asthma according to EPR-3 and GINA guidelines for at least six months. (See Attachment 3.) 8. FEV1 of 55-85% predicted measured >6 hours after the most recent use of a bronchodilator at screening. 9. Evidence of FEV1 reversibility at screening as demonstrated by an increase in FEV1 of at least 12% and 200 ml 15 to 30 minutes after administration of 4 puffs (360 mcg) of albuterol/salbutamol via a metered-dose inhaler (MDI) or 2.5 mg albuterol/salbutamol nebulized solution. Subjects suspected of being reversible but not meeting this criterion at Screening may have one repeat reversibility assessment within 7 days of the initial assessment. If a subject does not meet this reversibility criterion either at screening or at repeat assessment but has FEV1 reversibility documented within 12 months of screening, they may be included following discussion with the sponsor. 10. Score of 1.5 or greater on the Asthma Control Questionnaire (ACQ) at screening. 11. Short-acting beta-agonist (SABA) use ³5 times in the 2 weeks prior to screening. 12. Based on investigator's assessment, an adequate supply of albuterol/salbutamol in a MDI for use as a quick-relief medication as needed throughout the Run-in and Treatment Periods (other SABAs are not permitted). 13. Women must be one of the following: a.postmenopausal, b.surgically sterile. c.abstinent d.or if sexually active, be practicing an effective method of birth control which must be used consistently for 3 months prior to run-in as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study and for 6 months after the last dose of study drug. 14. Male subjects must consent to utilize a medically acceptable method of contraception throughout the study and for six months after the last dose of study drug and to not donate sperm during the study and for 6 months after receiving the last dose of study drug. Medically acceptable methods of contraception that may be used by the subject and/or the partner include diaphragm with vaginal spermicide, IUD, condom and partner using vaginal spermicide, surgical sterilization (6 months post surgery), post menopausal partner (not experiencing a menstrual period for a minimum of two years) and hormonal contraceptives (which must be used consistently for 3 months prior to run-in) such as oral contraceptives, hormonal patches, progestin implants or injections, and etonogestrel/ethinyl estradiol vaginal rings (NuvaRing). 15. Female subjects must have a negative serum pregnancy test at screening; and a negative urine pregnancy test at randomization. 16. Are considered eligible according to the following TB screening criteria: a.Have no history of latent or active TB prior to screening. b.Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination. c.Have had no recent close contact with a person with active TB or, if there has been such contact, have been evaluated by a physician specializing in TB and do not have evidence of, or require treatment for, latent TB. d.Within 6 weeks prior to the first administration of study agent, have negative TB screening test results (defined as either a negative Mantoux tuberculin skin test [TST] as outlined in Attachment 8, or a negative QuantiFERON-TB Gold test as outlined in Attachment 9) 17. Willing/able to adhere to the prohibitions and restrictions specified in this protocol.
|
|
E.4 | Principal exclusion criteria |
1. History of life-threatening asthma attack requiring intubation or ICU admission, hospitalization for asthma within 5 years of screening, or emergency department (ED) treatment of asthma within one (1) month of screening. 2. Have current signs or symptoms of liver insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive or uncontrolled in the investigator’s discretion. 3. History of drug/alcohol abuse within 5 years 4. Moderate or severe renal insufficiency as measured by creatinine clearance less than 50 mL/min as calculated by Cockcroft-Gault formula. 5. Positive anti-HCV, anti-HIV test, or evidence of HBV infection (positive HBsAg and/or HBcAb test) at screening 6. Cigarette smoking within 12 months prior to Screening or a greater than 10 pack year smoking history, as determined by medical history or subject’s verbal report. 7. Known allergies, hypersensitivity, or intolerance to JNJ-39758979 or its excipients (refer to Section 15.1 Physical Description of Study Drug(s) 8. Have received, or are expected to receive, any live virus, including FluMistâ, or bacterial vaccination within 1 month prior to the first administration of study agent, during the trial, or within 3 months after the last dose of study drug 9. Use of disallowed therapies: a. Systemic corticosteroids within 4 weeks of Week –2 (start of run-in period) b. Inhaled corticosteroids (ICS) within 2 weeks of Week -2 c. Long-acting beta agonists (LABA) within 1 week of Week –2 d. Oral beta agonists within 1 week of Week –2 e. Cromolyns, leukotriene inhibitors (zileuton, zafirlukast, montelukast), theophylline or inhaled anti-cholinergic agents within 1 week of Week -2 f. Omalizumab within 130 days (5 half-lives) of Week –2 10. Initiation or discontinuation of allergen immunotherapy within 3 months of Randomization (Stable doses of allergen immunotherapy are allowed). 11. History of upper respiratory infection (URI) [rhinitis or sinusitis] within 2 weeks of Week –2 (Start of Run-in Period). Subjects developing a URI between Week -2 and Randomization may repeat the Run-in Period after discussion with the medical monitor. 12. Screening or baseline (randomization) QTc (Fridericia) interval >450 msec (men) or >470 msec (women), or a history of additional risk factors for torsades de pointe (eg, heart failure, hypokalemia, family history of Long QT Syndrome) 13. Received an investigational drug or used an investigational medical device within 30 days before the planned start of treatment or are currently enrolled in an investigational study. 14. Pregnant or breast-feeding 15. Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements 16. Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Improvement in pre-bronchodilator FEV1 as measured by percent change from baseline in pre-bronchodilator % predicted FEV1 value at Week 12
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |